论文部分内容阅读
目的探讨微泵与非微泵静脉输注乌司他丁治疗重症急性胰腺炎疗效的差异及乌司他丁的最佳用药剂量。方法将94例重症急性胰腺炎患者随机分为两组,实验组(46例)应用微泵静脉输注乌司他丁;对照组(48例)乌司他丁经静脉全身给药。比较两组临床症状体征、实验室数据及远期并发症的差异。结果①实验组腹痛、腹胀、压痛消失的时间均短于对照组(P<005),中转急诊手术率低于对照组。②实验组患者的第3天、第7天血淀粉酶、尿淀粉酶、血糖、白细胞亦均低于对照组(P<0.05)。③并发症假性胰腺囊肿发生率两组无显著差异(P>0.05),与是否合用生长抑素密切相关(P<0.05)。结论微泵静脉输注乌司他丁治疗重症急性胰腺炎疗效好、剂量小。远期并发症的防治建议联合应用生长抑素。
Objective To investigate the differences between curative effect of ulinastatin and non-micro-pump venous infusion in severe acute pancreatitis and the optimal dose of ulinastatin. Methods 94 cases of severe acute pancreatitis were randomly divided into two groups. The experimental group (46 cases) received intravenous injection of ulinastatin and the control group (48 cases) of ulinastatin via systemic intravenous injection. Differences in clinical signs, laboratory data and long-term complications were compared between the two groups. Results ① The time of abdominal pain, abdominal distension and tenderness disappearing in the experimental group was shorter than that of the control group (P <005). The rate of emergency operation in the transit group was lower than that of the control group. ② The levels of serum amylase, urine amylase, blood glucose and leukocyte in the experimental group were also lower than those in the control group on the 3rd and 7th day (P <0.05). There was no significant difference between the two groups in the incidence of complications (P> 0.05), and the combination of somatostatin (P <0.05). Conclusion Micro-pump intravenous ulinastatin treatment of severe acute pancreatitis with good efficacy, small dose. Prevention and treatment of long-term complications suggest the combination of somatostatin.